Clinical Trial Update: Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

View source ↗

Summary

This completed observational study evaluates the safety and efficacy of NovoSeven (recombinant activated factor VII) in individuals with congenital Factor VII d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Factor Vii Deficiency

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Congenital FVII Deficiency | Status: COMPLETED